BiotechTube

TSHA-101

Phase 1/2Active
0 watching 0 views this week💤 Quiet
36
Hype Score

Development Stage

✓
Pre-clinical
2
Phase 1
3
Phase 2
4
Phase 3
5
Approved
Indication / Disease

Infantile GM2 Gangliosidosis (Disorder)

Conditions

Infantile GM2 Gangliosidosis (Disorder)

Trial Timeline

Mar 12, 2021 → Mar 12, 2027

NCT ID
NCT04798235

About TSHA-101

TSHA-101 is a phase 1/2 stage product being developed by Taysha Gene Therapies for Infantile GM2 Gangliosidosis (Disorder). The current trial status is active. This product is registered under clinical trial identifier NCT04798235. Target conditions include Infantile GM2 Gangliosidosis (Disorder).

Hype Score Breakdown

Clinical
13
Activity
8
Company
5
Novelty
4
Community
3

Clinical Trials (1)

NCT IDPhaseStatus
NCT04798235Phase 1/2Active

Competing Products

16 competing products in Infantile GM2 Gangliosidosis (Disorder)

See all competitors
ProductCompanyStageHype Score
MAS825 + PlaceboNovartisPhase 2
52
alglucosidase alfa + alglucosidase alfaSanofiApproved
84
MyozymeSanofiPhase 2
51
Bacillus Clausii Multi ATB Resist + PlaceboSanofiApproved
84
RadiprodilUCBPhase 2
49
Larotrectinib (Vitrakvi, BAY2757556) + Standard of CareBayerPre-clinical
20
Sabril®LundbeckPre-clinical
20
VigabatrinLundbeckApproved
82
NusinersenBiogenPre-clinical
20
GWP42003-PJazz PharmaceuticalsPhase 3
74
GWP42003-PJazz PharmaceuticalsPhase 3
74
Cerliponase AlfaBioMarin PharmaceuticalPre-clinical
20
Cholic AcidsMirum PharmaceuticalsPhase 3
74
Cipaglucosidase alfa + MiglustatAmicus TherapeuticsPhase 3
74
ATB200 + AT2221Amicus TherapeuticsPre-clinical
20
RP-L401Rocket PharmaceuticalsPhase 1
25